Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValereum Plc Regulatory News (VLRM.PL)

Share Price Information for Valereum Plc (VLRM.PL)

Share Price is delayed by 15 minutes
Get Live Data
2.27    0.00 (0.00%)
Bid:
2.24
Ask:
2.30
Spread: 0.06 (2.679%)
Market Cap: £12.31m
VLRM.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Valereum Plc Share Chart

Remuneration Update - Warrant and Option Issue

31 May 2024 10:10

RNS Number : 6521Q
Valereum PLC
31 May 2024
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR")

 

31/05/2024

Valereum Plc

("Valereum" or the "Company")

Remuneration update - Warrant and Option Issue

 

Remuneration update

Valereum Plc (AQSE: VLRM) proposed at its Shareholder Meeting held on the 22nd February 2024 its intention to align management and employee incentives and rewards. Following the conclusion of the Board's transition in November 2023, the Valereum team have established solid foundations for growth and the Board (following a proposal by the Remuneration Committee) resolved to implement a compensation plan with a focus on aligning the Valereum workforce's interests with those of the Company's shareholders.

 

The primary objectives of the compensation plan are to:

 

● conserve cash flows to support the development of the business through keeping cash-based remuneration low;

● create a 'partnership culture' whereby employees are incentivised to focus on maximising the pace of growth in shareholder value, by developing the Company rapidly through maximising group revenues and profitability whilst maintaining and operating a tightly controlled cost base; and

● provide compensation upside based on growing shareholder value.

 

Cash-based remuneration for all employees including the Board (individually) has been capped at £120,000 per annum (plus any statutory minimum levels of pension contributions where applicable), and share options (to the extent tax advantageous) and otherwise warrants have been issued to ensure the Valereum workforce is incentivised to deliver sustained growth in shareholder value.

 

Following a proposal by the Remuneration Committee and subsequent Board approval, 9,000,000 share options over ordinary shares of £0.001 each in the Company have been issued to the non-Board employees and share options (to the extent tax advantageous) and otherwise warrants over ordinary shares of £0.001 each in the Company have been issued to the Executive and Non-Executive Directors as follows: James Formolli 4,807,692; Nicholas Cowan 10,000,000; Peter Sekhon 5,000,000; Karl Moss 5,000,000; Gary Cottle 5,000,000; and Simon Brickles 3,000,000.

 

The share options are tax-advantaged options that require a minimum holding period of 2 years from the date of being granted to qualify for the full tax advantages and all shares acquired under the share options and warrants are subject to a lock-in period of 1 year from the date of issue of the share option or warrant. The share options and the warrants are exercisable at a cost of £0.001 per share and expire after 10 years and will be forfeited in the event an employee leaves the Company.

 

To conserve cash over the longer term through minimising cash-based remuneration and to provide further incentivisation to the Valereum workforce to perform strongly and increase the value of the Company, the Board has also approved a rolling annual share option incentive plan amounting to 5% of the average equity share capital in issue in each preceding year involving the discretionary award of options based on performance and contribution to the development of the Company.

 

To further incentivise and reward the Valereum workforce for delivering growth in market capitalisation, a market capitalisation performance incentive has been approved whereby options amounting to 5% of the outstanding shares in issue will be awarded if the Company achieves each of the market capitalisations as follows:

 

● £50,000,000 Market Capitalisation

● £100,000,000 Market Capitalisation

● £150,000,000 Market Capitalisation

● £200,000,000 Market Capitalisation

 

In each case for a consecutive period of 10 days. The options will be allocated on a discretionary basis based on Remuneration Committee recommendations to the Board and the exercise price of the options will be based on the average closing share price in the 3 months before the date of award and will vest over 4 equal six monthly tranches over 2 years.

 

The remuneration as outlined above will be subject to annual reviews commencing 1st January 2025 in consideration of the Company's performance in the preceding calendar year.

James Formolli, Executive Chairman, of Valereum Plc commented:

"The remuneration package that we have outlined above is specifically designed to conserve the Company's cash as well as ensure that our team is aligned with our shareholders as we look to deliver Valereum's significant potential."

For further information please contact:

 

Valereum Plc

James Formolli, Chairman

Tel: +971 4584 6284

 

Stanford Capital Partners

Tel: 023 3650 3650

Bob Pountney

Patrick Claridge

 

 AQSE Corporate Adviser

First Sentinel Corporate Finance

Brian Stockbridge

Tel: +44 20 3855 5551

 

Further announcements to follow in due course.

 

The directors of the Company accept responsibility for the contents of this announcement.

 

For more information, please visit the Company's website at vlrm.com

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1) James Formolli

2) Nicholas Cowan

3) Peter Sekhon

4) Karl Moss

5) Gary Cottle

6) Simon Brickles

2.

Reason for the Notification

a)

Position/status

1) James Formolli, Chairman

2) Nicholas Cowan, CEO

3) Peter Sekhon, Investor Relations Director

4) Karl Moss, Chief Financial Officer

5) Gary Cottle, Non-executive Director

6) Simon Brickles, Non-executive Director

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Valereum Plc

b)

LEI

213800EJ8BFEQQ9POX79

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.1p each

Identification Code

GI000A1171Y8

b)

Nature of the transaction

Grant of options and or warrants

c)

Price(s) and volume(s)

 

Price 

Volume 

1) £0.001

2) £0.001

3) £0.001

4) £0.001

5) £0.001

6) £0.001

1) 4,807,692

2) 10,000,000

3) 5,000,000

4) 5,000,000

5) 5,000,000

6) 3,000,000

d)

Aggregated information:

· Aggregated volume

· Price

 

Single transaction, see details in item (c) above

e)

Date of the transaction

31 May 2024

f)

Place of the Transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXWPUBUAUPCUBG
Date   Source Headline
5th Jun 20264:32 pmRNS-RValereum Vox Issue 4 Published
1st Jun 20267:00 amRNSHolding(s) in Company
22nd May 20263:00 pmRNS-RValereum Vox Issue 3 Published
15th May 20267:00 amRNSPlacing and Subscription Raising £1,050,000
11th May 20264:10 pmRNS-RValereum Vox Issue 2 Published
23rd Apr 20261:45 pmRNS-RLaunch of new blog, Valereum Vox
22nd Apr 20267:00 amRNSDefinitive Agreement with QGP
21st Apr 20267:00 amRNSSettlement Agreement with Blubird
16th Apr 20267:00 amRNSDefinitive Agreement Update
10th Apr 20262:48 pmRNSReplacement - Coupon Payment Received
10th Apr 20262:07 pmRNSCoupon Payment Received
9th Apr 202611:32 amRNSShare Options and PDMR Dealings
31st Mar 20261:46 pmRNSInvestor Meeting
31st Mar 20267:31 amRNSProposed Strategic Integration and Coupon Payment
4th Mar 20267:00 amRNSOTCQB Approval
27th Feb 202610:53 amRNSVLRM Markets Organisational Update
25th Feb 20267:00 amRNSOption Agreement to Cancel 2 Million Warrants
16th Feb 20267:00 amRNSDirectorate Changes
16th Feb 20267:00 amRNSSigning of MoU with Integra Foundation
9th Feb 20267:00 amRNSSigning of MoU with RWA.io & Defactor
6th Feb 20267:00 amRNSChanges to Board of Directors
30th Jan 20262:00 pmRNSHolding(s) in Company
29th Jan 20267:00 amRNSSigning of MoU and Exercise of Warrants
27th Jan 20263:50 pmRNSHolding(s) in Company
26th Jan 20267:00 amRNSForward Strategy Update
21st Jan 20267:00 amRNSAgreement and Lifting of Suspension
22nd Dec 20257:00 amRNSContract
22nd Dec 20257:00 amRNSContract
17th Dec 20257:00 amRNSResignation of Corporate Adviser and Suspension
4th Dec 202510:56 amRNS-ROTC Application
2nd Dec 202510:34 amRNSUpdate on Capital Raise
25th Nov 20257:00 amRNSAgreement to Raise Capital
21st Nov 20257:00 amRNSExercise of Warrants
17th Nov 20257:00 amRNSCompletion of Subscription
14th Nov 20257:00 amRNSDeployment of DigiShares’ Tokenisation Platform
27th Oct 20257:00 amRNS-RCOINGT to List on VLRM Markets
10th Oct 20257:00 amRNSSubscription to Raise £600,000
7th Oct 20257:00 amRNSVLRM Markets’ Post Launch Update
1st Oct 20259:00 amRNSOption Agreement to Cancel 2m Warrants
25th Sep 20257:00 amRNSValereum Advances GATE Token Strategy
24th Sep 20254:47 pmRNSHolding(s) in Company
24th Sep 20257:00 amRNSInterim Results
19th Sep 20257:00 amRNS-RUpdate on Strategy Implementation
10th Sep 20257:00 amRNS-RVLRM to Co-host Exclusive Side Event at TOKEN2049
4th Sep 20257:00 amRNS-RCrypto and Multi Currency Payroll Solution
20th Aug 20251:00 pmRNS-RStrategic Collaboration with ZIGChain & DigiShares
18th Aug 20257:00 amRNS-RIndirect Investee Update
14th Aug 20257:00 amRNSResult of WRAP Retail Offer
11th Aug 20254:30 pmRNSWRAP Retail Offer for up to £100,000
11th Aug 20257:00 amRNSStrategic Investment in Metrikus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.